{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:05:14Z","timestamp":1790057114379,"version":"4.0.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Catatonia is a well-recognized psychiatric emergency with an evolving understanding of its underlying pathophysiology. However, withdrawal-associated catatonia remains poorly characterized. Here we describe a 32-year-old man with symptoms consistent with methamphetamine-withdrawal catatonia, a previously undescribed etiology, which resolved only after treatment with mixed amphetamine salts. The patient remained catatonic (Bush-Francis Catatonia Rating Scale [BFCRS] &amp;gt;10) for four months despite 38 sessions of electroconvulsive therapy, lorazepam up to 24 mg daily, and multiple augmentation strategies. An extensive medical and neurologic workup excluded alternative causes. Following initiation of mixed amphetamine salts, his BFCRS decreased from 15 to 6 within 48 hours, with sustained resolution and no recurrence of psychosis despite discontinuation of antipsychotics. This case suggests that methamphetamine withdrawal may represent an underrecognized cause of catatonia and that dopaminergic augmentation may have a therapeutic role in refractory cases.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1947002","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:10Z","timestamp":1790055550000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Methamphetamine-withdrawal catatonia resolved with mixed amphetamine salts: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Elischa J.","family":"Sanders","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital","place":["Boston, MA, United States"]},{"name":"Psychotic Disorders Division, McLean Hospital","place":["Belmont, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie C.","family":"Valcourt","sequence":"additional","affiliation":[{"name":"Psychotic Disorders Division, McLean Hospital","place":["Belmont, MA, United States"]},{"name":"Department of Psychiatry, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.schres.2013.04.034","article-title":"Catatonia in DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr Res"},{"key":"B2","volume-title":"Catatonia: A Clinician\u2019s Guide to Diagnosis and Treatment","author":"Fink","year":"2006"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(19)30190-7","article-title":"Catatonia and the immune system: a review","volume":"6","author":"Rogers","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(18)30474-7","article-title":"Structure and neural mechanisms of catatonia","volume":"6","author":"Walther","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2017.06.011","article-title":"Alternative treatment strategies for catatonia: a systematic review","volume":"48","author":"Beach","year":"2017","journal-title":"Gen Hosp Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.12788\/acp.0116","article-title":"Methamphetamine-associated catatonia: Case series and systematic review of the literature from 1943-2020","volume":"35","author":"Slavnic","year":"2023","journal-title":"Ann Clin Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"21c403211","DOI":"10.4088\/pcc.21cr03211","article-title":"Methamphetamine-induced catatonia","volume":"24","author":"Sullivan","year":"2022","journal-title":"Prim Car Companion CNS Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0000000000000462","article-title":"Clozapine withdrawal-induced Malignant catatonia or neuroleptic Malignant syndrome: A case report and a brief review of the literature","volume":"44","author":"Belteczki","year":"2021","journal-title":"Clin Neuropharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2020.102043","article-title":"Clozapine withdrawal Malignant catatonia in a medical intensive care unit setting","volume":"52","author":"Brailey","year":"2020","journal-title":"Asian J Psychiatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0192-9","article-title":"Review of withdrawal catatonia: what does this reveal about clozapine","volume":"8","author":"Lander","year":"2018","journal-title":"Transl Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6817a3","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential \u2014 United states, 2003\u20132017","volume":"68","author":"Kariisa","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/yco.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.1990.tb01626.x","article-title":"Chronic schizophrenia-like states in methamphetamine psychosis","volume":"44","author":"Tomiyama","year":"1990","journal-title":"Japanese J Psychiatry Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2402731","article-title":"Catatonia secondary to sudden clozapine withdrawal: a case with three repeated episodes and a literature review","volume":"2017","author":"Bilbily","year":"2017","journal-title":"Case Rep Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pop.2010.11.004","article-title":"Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy","volume":"38","author":"Ciccarone","year":"2011","journal-title":"Prim Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2011.86","article-title":"Decreased dopamine activity predicts relapse in methamphetamine abusers","volume":"17","author":"Wang","year":"2012","journal-title":"Mol Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.36131\/cnfioritieditore20250306","article-title":"Does dysregulation of the indirect pathway contribute to the pathophysiology of catatonia through neurotransmitter imbalance","volume":"22","author":"Seif","year":"2025","journal-title":"Clin Neuropsychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.993671","article-title":"Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence","volume":"15","author":"Ariza-Salamanca","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/bf02854904","article-title":"Causes and consequences of methamphetamine and MDMA toxicity","volume":"8","author":"Quinton","year":"2006","journal-title":"AAPS J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.03.009","article-title":"Methamphetamine: Effects on the brain, gut and immune system","volume":"120","author":"Prakash","year":"2017","journal-title":"Pharmacol Res"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1947002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:11Z","timestamp":1790055551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1947002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":21,"alternative-id":["10.3389\/fpsyt.2026.1947002"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1947002","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1947002"}}